Novo Nordisk has made its smart insulin pens available in the UK, giving people treated within the NHS for diabetes access to devices that can monitor and record dosing information for the first time.
Long-acting insulin helps people with diabetes maintain normal blood sugar levels throughout the day. Unlike short-acting insulin, it never peaks, keeping an even sugar level in your blood.
Smart insulin pens are expected to drive the insulin pen market from $13.8 billion in 2020 to more than $16 billion by 2030, according to GlobalData.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback